Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Non Operating Income (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Non Operating Income for 9 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 120.07% year-over-year to -$1.3 million, compared with a TTM value of -$1.5 million through Dec 2025, down 156.6%, and an annual FY2025 reading of -$1.5 million, down 275.99% over the prior year.
  • Non Operating Income was -$1.3 million for Q4 2025 at Puma Biotechnology, down from $115000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.6 million in Q2 2021 and bottomed at -$8.0 million in Q3 2023.
  • Average Non Operating Income over 5 years is $558800.0, with a median of $46000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income soared 14919.48% in 2021, then crashed 5366.67% in 2024.
  • Year by year, Non Operating Income stood at -$2.4 million in 2021, then soared by 430.01% to $7.9 million in 2022, then grew by 10.42% to $8.7 million in 2023, then dropped by 24.4% to $6.6 million in 2024, then tumbled by 120.07% to -$1.3 million in 2025.
  • Business Quant data shows Non Operating Income for PBYI at -$1.3 million in Q4 2025, $115000.0 in Q3 2025, and $410000.0 in Q2 2025.